RyersonLZFoleyJChangI, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology2019; 93(15): e1452–e1462.
2.
van KempenZLEHoogervorstELJWattjesMP, et al. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. Neurology2020; 95(6): e745–e754.
3.
RolfesLMeuthS. Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing – YES. Mult Scler2021.
4.
RolfesLPawlitzkiMPfeufferS, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm2021; 8(5): e1035.
5.
BakerDPryceGJamesLK, et al. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Mult Scler Relat Disord2020; 44: 102279.
6.
van KempenZHLKillesteinJ. Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“No.”Mult Scler2021.
7.
Simpson-YapSDe BrouwerEKalincikT, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology2021; 97: e1870–e1885.
8.
Sharifian-DorcheMSahraianMAFaddaG, et al. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Mult Scler Relat Disord2021; 50: 102800.
ApostolidisSAKakaraMPainterMM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med2021; 27(11): 1990–2001.
